Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pamalican Asset Management just snagged 6,900 shares of Regeneron Pharmaceuticals, making the biotech giant its 16th largest ...

Research analysts at Leerink Partnrs dropped their FY2026 earnings per share estimates for Alnylam Pharmaceuticals in a ...

Biotech stocks toppled early Thursday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe ...

Fintel reports that on March 28, 2025, Leerink Partners downgraded their outlook for Equillium (LSE:0A4D) from Outperform to Market Perform. There are 35 funds or institutions reporting positions ...

At the low end of effective tax rates is Regeneron Pharmaceuticals (NASDAQ: REGN), which has issued effective tax rate guidance for 2025 of 9% to 11%. With manufacturing split between Rensselaer ...

Since then, RGNX has gained (% wise) what SRPT has lost. Leerink notes that shares of Outperform-rated Sarepta are under pressure on the heels of the disclosure of a patient death following ...

Fintel reports that on March 21, 2025, Leerink Partners downgraded their outlook for Elevation Oncology (NasdaqGS:ELEV) from Outperform to Market Perform. Analyst Price Forecast Suggests 2,468.35% ...